Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Sex differences in efficacy and toxicity of systemic treatments in onoclogy

Sabine Oertelt-Prigione • 11 Sep 2022
ESMO 2022
General

Sabine Oertelt-Prigione, MD, PhD, Radboud University, Nijmegen, The Netherlands, discusses sex differences in efficacy and toxicity of systemic treatments in the field of oncology where women tend to experience more side effects and side effects often correlate with dosage and potential efficacy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sabine Oertelt-Prigione

0:43
How can sex- and gender-sensitive research and practice be better implemented?
Sabine Oertelt-Prigione • 11 Sep 2022
0:45
The ESMO Gender Medicine Task Force
Sabine Oertelt-Prigione • 11 Sep 2022
1:08
Effects of gender differences on quality of life studies
Sabine Oertelt-Prigione • 11 Sep 2022
4:17
Sex and gender differences in medicine
Sabine Oertelt-Prigione • 17 Sep 2020

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals